With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
The Chinese cell therapy specialist, whose core product is still in phase 1 trials, will avoid future cash flow difficulties by selling itself to the European giant Key Takeaways: AstraZeneca…
Recent Articles
RELATED ARTICLES
-
FAST NEWS: Gracell shareholders approve merger with AstraZeneca
GRCL.US -
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
- CHINA BULLETIN: China-India Tensions Flare with New Arrests
- CHINA BULLETIN: PMI Readings Signal Strong End to 2023
-
Akeso marks profit milestone with swift rights issue
9926.HK
- ProfoundBio discovers the joys of having a wealthy owner
